Literature DB >> 29280057

Effects of Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease in an Obese Rat Model.

Kiminori Watanabe1, Masayuki Ohta2, Hiroomi Takayama2, Kazuhiro Tada2, Yuki Shitomi2, Takahide Kawasaki2, Yuichiro Kawano2, Yuichi Endo2, Yukio Iwashita2, Masafumi Inomata2.   

Abstract

BACKGROUND/AIM: Laparoscopic sleeve gastrectomy (SG) is an increasingly used bariatric surgery, which is reported to be effective for nonalcoholic fatty liver disease (NAFLD). Recently, activation of farnesoid X receptor (FXR), which is a nuclear receptor of bile acid (BA), was reported to contribute to the resolution of NAFLD. However, it is unclear whether SG has an effect on expression of FXR in the liver. We aimed to investigate the expression of FXR and its related factors in the liver after SG and to clarify the relationship between changes in FXR expression and NAFLD in an obese rat model.
METHODS: Thirty male Zucker fatty rats were divided into three groups: sham-operated (SO) control, pair-fed (PF) control, and SG. Eight weeks after the surgery, metabolic parameters, plasma levels of total BA and liver enzymes, liver triglyceride (TG) content, and mRNA expression of FXR and its related factors, such as small heterodimer partner (SHP) and peroxisome proliferator-activated receptor α (PPARα), were measured.
RESULTS: Metabolic parameters in the SG group were significantly improved compared with the SO group. Liver enzymes and TG were significantly lower in the SG group than in the SO group. Plasma levels of BA were significantly higher in the SG group than in the SO and PF groups. mRNA expression of FXR, SHP, and PPARα in the liver was significantly higher in the SG group than in the SO group.
CONCLUSIONS: These results suggest that the effects of SG on NAFLD should be associated with the expression of the FXR pathway in the liver in a Zucker fatty rat model.

Entities:  

Keywords:  Bariatric surgery; Bile acid; Farnesoid X receptor; NAFLD; Sleeve gastrectomy

Mesh:

Substances:

Year:  2018        PMID: 29280057     DOI: 10.1007/s11695-017-3052-4

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  42 in total

1.  Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Ann Med       Date:  2010-11-02       Impact factor: 4.709

2.  Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease.

Authors:  Zhao-Xia Yang; Wei Shen; Hang Sun
Journal:  Hepatol Int       Date:  2010-08-12       Impact factor: 6.047

3.  Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes.

Authors:  Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap
Journal:  N Engl J Med       Date:  2014-03-31       Impact factor: 91.245

Review 4.  Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis.

Authors:  Rajasekhara R Mummadi; Krishna S Kasturi; Swapna Chennareddygari; Gagan K Sood
Journal:  Clin Gastroenterol Hepatol       Date:  2008-08-19       Impact factor: 11.382

5.  Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model.

Authors:  Yoshihiro Kamada; Hitoshi Matsumoto; Shinji Tamura; Juichi Fukushima; Shinichi Kiso; Koji Fukui; Takumi Igura; Norikazu Maeda; Shinji Kihara; Tohru Funahashi; Yuji Matsuzawa; Iichiro Shimomura; Norio Hayashi
Journal:  J Hepatol       Date:  2007-04-09       Impact factor: 25.083

6.  Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.

Authors:  Inés Pineda Torra; Thierry Claudel; Caroline Duval; Vladimir Kosykh; Jean-Charles Fruchart; Bart Staels
Journal:  Mol Endocrinol       Date:  2003-02

7.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

8.  Identification of a nuclear receptor that is activated by farnesol metabolites.

Authors:  B M Forman; E Goode; J Chen; A E Oro; D J Bradley; T Perlmann; D J Noonan; L T Burka; T McMorris; W W Lamph; R M Evans; C Weinberger
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

Review 9.  Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis.

Authors:  Katherine M Flegal; Brian K Kit; Heather Orpana; Barry I Graubard
Journal:  JAMA       Date:  2013-01-02       Impact factor: 56.272

Review 10.  Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Viktoria L Gloy; Matthias Briel; Deepak L Bhatt; Sangeeta R Kashyap; Philip R Schauer; Geltrude Mingrone; Heiner C Bucher; Alain J Nordmann
Journal:  BMJ       Date:  2013-10-22
View more
  3 in total

Review 1.  Comparative effectiveness of medical treatment vs. metabolic surgery for histologically proven non-alcoholic steatohepatitis and fibrosis: a matched network meta-analysis.

Authors:  Adrian T Billeter; Beatrice Reiners; Svenja E Seide; Pascal Probst; Eva Kalkum; Christian Rupp; Beat P Müller-Stich
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

2.  Farnesoid X receptor - a molecular predictor of weight loss after vertical sleeve gastrectomy?

Authors:  F Scott; S Elahi; M Adebibe; U Parampalli; K Mannur; A Góralczyk; G J Sanger
Journal:  Obes Sci Pract       Date:  2019-03-26

3.  Secondary Unconjugated Bile Acids Induce Hepatic Stellate Cell Activation.

Authors:  Kunihiro Saga; Yukio Iwashita; Shinya Hidano; Yuiko Aso; Kenji Isaka; Yasutoshi Kido; Kazuhiro Tada; Hiroomi Takayama; Takashi Masuda; Teijiro Hirashita; Yuichi Endo; Masayuki Ohta; Takashi Kobayashi; Masafumi Inomata
Journal:  Int J Mol Sci       Date:  2018-10-05       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.